Published in Am J Hematol on May 01, 2009
Advances in the understanding of myeloma bone disease and tumour growth. Br J Haematol (2010) 1.13
The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia (2012) 1.07
A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes. Clin Cancer Res (2010) 1.07
A mathematical model of bone remodeling dynamics for normal bone cell populations and myeloma bone disease. Biol Direct (2010) 0.99
Enhancement of 26S proteasome functionality connects oxidative stress and vascular endothelial inflammatory response in diabetes mellitus. Arterioscler Thromb Vasc Biol (2012) 0.98
Tumor-host cell interactions in the bone disease of myeloma. Bone (2010) 0.96
MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells. Blood (2014) 0.95
Osteoblastogenesis and tumor growth in myeloma. Leuk Lymphoma (2010) 0.93
Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib. PLoS One (2013) 0.91
Identification of nitric oxide as an endogenous inhibitor of 26S proteasomes in vascular endothelial cells. PLoS One (2014) 0.86
Regulation of the proteasome by AMPK in endothelial cells: the role of O-GlcNAc transferase (OGT). PLoS One (2012) 0.84
Loss of a 20S proteasome activator in Saccharomyces cerevisiae downregulates genes important for genomic integrity, increases DNA damage, and selectively sensitizes cells to agents with diverse mechanisms of action. G3 (Bethesda) (2012) 0.84
Myeloma cell-derived Runx2 promotes myeloma progression in bone. Blood (2015) 0.83
Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo. Exp Hematol (2013) 0.81
Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling. Biomed Res Int (2015) 0.80
Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma. Cancer Res (2016) 0.77
Effects of proteasome inhibitors on bone cancer. Bonekey Rep (2013) 0.77
Negatively charged metal oxide nanoparticles interact with the 20S proteasome and differentially modulate its biologic functional effects. ACS Nano (2013) 0.76
Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers. J Proteomics (2016) 0.76
Bone marker gene expression in calvarial bones: different bone microenvironments. J Biol Res (Thessalon) (2017) 0.75
Inhibition of the Proteasome β2 Site Sensitizes Triple-Negative Breast Cancer Cells to β5 Inhibitors and Suppresses Nrf1 Activation. Cell Chem Biol (2017) 0.75
Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors. Bone (2013) 0.75
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res (2001) 6.93
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood (2002) 3.62
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol (2004) 3.49
Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med (1974) 2.97
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res (2002) 2.83
Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice. J Immunol (1979) 2.60
Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res (2007) 2.50
Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest (2003) 2.30
The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol (2009) 2.12
Serum concentration and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiologic significance. J Lab Clin Med (1993) 1.79
Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood (2007) 1.75
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood (2007) 1.75
Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood (2003) 1.56
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol (2006) 1.56
The pathogenesis of the bone disease of multiple myeloma. Bone (2008) 1.51
Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. Blood (1999) 1.40
Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. Cancer Res (2005) 1.39
Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging. Mol Cancer Ther (2007) 1.28
Progressively impaired proteasomal capacity during terminal plasma cell differentiation. EMBO J (2006) 1.27
Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma. Blood (2006) 1.22
Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. Br J Haematol (2007) 1.19
Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits. Cancer (2008) 1.07
Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma. Int J Hematol (2007) 0.94
Bone morphogenetic proteins. Growth Factors (2004) 8.61
E3 ubiquitin ligase Smurf1 mediates core-binding factor alpha1/Runx2 degradation and plays a specific role in osteoblast differentiation. J Biol Chem (2003) 2.34
CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease. Blood (2012) 2.18
Proteolysis of latent transforming growth factor-beta (TGF-beta )-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J Biol Chem (2002) 1.99
Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. Blood (2011) 1.88
Bone morphogenetic protein receptor signaling is necessary for normal murine postnatal bone formation. J Cell Biol (2002) 1.88
Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res (2006) 1.82
Smurf1 inhibits osteoblast differentiation and bone formation in vitro and in vivo. J Biol Chem (2003) 1.81
Advances in osteoclast biology: old findings and new insights from mouse models. Nat Rev Rheumatol (2011) 1.76
Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood (2007) 1.75
Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1. Cancer Res (2012) 1.75
Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases. Cancer Res (2012) 1.65
The hedgehog signaling molecule Gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastatic human breast cancer cells. Cancer Res (2006) 1.62
Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer (2003) 1.58
Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP). Bone (2004) 1.57
TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling. Cancer Res (2010) 1.57
Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood (2003) 1.56
Silent information regulator (Sir)T1 inhibits NF-κB signaling to maintain normal skeletal remodeling. J Bone Miner Res (2013) 1.54
Advances in the biology of bone metastasis: how the skeleton affects tumor behavior. Bone (2010) 1.54
C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res (2003) 1.52
The pathogenesis of the bone disease of multiple myeloma. Bone (2008) 1.51
Caspase-2 deficiency enhances aging-related traits in mice. Mech Ageing Dev (2006) 1.46
The zinc finger transcription factor Gli2 mediates bone morphogenetic protein 2 expression in osteoblasts in response to hedgehog signaling. Mol Cell Biol (2006) 1.45
Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis. Mol Cancer (2010) 1.45
Model structure and control of bone remodeling: a theoretical study. Bone (2008) 1.44
Wnt/β-catenin signaling activates bone morphogenetic protein 2 expression in osteoblasts. Bone (2012) 1.38
NF-kappaB specifically activates BMP-2 gene expression in growth plate chondrocytes in vivo and in a chondrocyte cell line in vitro. J Biol Chem (2003) 1.35
Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev (2010) 1.32
Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood (2004) 1.29
Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging. Mol Cancer Ther (2007) 1.28
Longitudinal live animal micro-CT allows for quantitative analysis of tumor-induced bone destruction. Bone (2010) 1.26
Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells. PLoS One (2012) 1.25
Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin Cancer Res (2008) 1.24
Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. Br J Haematol (2007) 1.19
Eph receptors and ephrin signaling pathways: a role in bone homeostasis. Int J Med Sci (2008) 1.17
The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Res Treat (2002) 1.15
Inhibition of TGF-β signaling by 1D11 antibody treatment increases bone mass and quality in vivo. J Bone Miner Res (2010) 1.15
Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo. J Clin Invest (2002) 1.12
Inhibition of microtubule assembly in osteoblasts stimulates bone morphogenetic protein 2 expression and bone formation through transcription factor Gli2. Mol Cell Biol (2008) 1.10
Anti-transforming growth factor ß antibody treatment rescues bone loss and prevents breast cancer metastasis to bone. PLoS One (2011) 1.08
Quantitative measures of femoral fracture repair in rats derived by micro-computed tomography. J Biomech (2009) 1.05
A murine model of myeloma that allows genetic manipulation of the host microenvironment. Dis Model Mech (2009) 1.04
Differential effects between the loss of MMP-2 and MMP-9 on structural and tissue-level properties of bone. J Bone Miner Res (2011) 1.04
Matrix rigidity induces osteolytic gene expression of metastatic breast cancer cells. PLoS One (2010) 1.03
Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma. Cancer (2003) 0.99
Transcriptional regulation of BMP2 expression by the PTH-CREB signaling pathway in osteoblasts. PLoS One (2011) 0.98
Theoretical investigation of the role of the RANK-RANKL-OPG system in bone remodeling. J Theor Biol (2009) 0.98
Osteoclast-derived matrix metalloproteinase-7, but not matrix metalloproteinase-9, contributes to tumor-induced osteolysis. Cancer Res (2009) 0.98
Zerumbone abolishes RANKL-induced NF-kappaB activation, inhibits osteoclastogenesis, and suppresses human breast cancer-induced bone loss in athymic nude mice. Cancer Res (2009) 0.97
Pharmacologic and genetic manipulation of MMP-2 and -9 affects retinal neovascularization in rodent models of OIR. Invest Ophthalmol Vis Sci (2007) 0.95
Bmp2 in osteoblasts of periosteum and trabecular bone links bone formation to vascularization and mesenchymal stem cells. J Cell Sci (2013) 0.92
Gr-1+CD11b+ myeloid-derived suppressor cells: formidable partners in tumor metastasis. J Bone Miner Res (2010) 0.92
Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts. J Bone Miner Res (2010) 0.88
Transdermal lovastatin enhances fracture repair in rats. J Bone Miner Res (2008) 0.85
Microtubule assembly affects bone mass by regulating both osteoblast and osteoclast functions: stathmin deficiency produces an osteopenic phenotype in mice. J Bone Miner Res (2011) 0.85
Advances in the management of myeloma bone disease. Expert Opin Pharmacother (2005) 0.83
Functional redundancy of type II BMP receptor and type IIB activin receptor in BMP2-induced osteoblast differentiation. J Cell Physiol (2012) 0.83
Bone metastasis: can osteoclasts be excluded? Nature (2007) 0.81
Bisphosphonates and tumor burden. J Clin Oncol (2002) 0.80
Absence of interleukin-3 does not affect the severity of local and systemic anaphylaxis but does enhance eosinophil infiltration in a mouse model of allergic peritonitis. Immunol Lett (2004) 0.80
Bone marrow-targeted liposomal carriers. Expert Opin Drug Deliv (2011) 0.79
6-Thioguanine inhibition of parathyroid hormone-related protein expression is mediated by GLI2. Anticancer Res (2011) 0.78
Third North American Symposium on Skeletal Complications of Malignancy: summary of the scientific sessions. Cancer (2003) 0.77
Calmodulin kinase II inhibition disrupts cardiomyopathic effects of enhanced green fluorescent protein. J Mol Cell Cardiol (2007) 0.76
[A multicenter retrospective etiological analysis of 601 patients with hemophagocytic lymphohistiocytosis in China]. Zhonghua Nei Ke Za Zhi (2015) 0.75
A sustained release of lovastatin from biodegradable, elastomeric polyurethane scaffolds for enhanced bone regeneration. Tissue Eng Part A (2010) 0.75
Epinephrine Stimulates Cell Proliferation and Induces Chemoresistance in Myeloma Cells through the β-Adrenoreceptor in vitro. Acta Haematol (2017) 0.75
In memoriam; Dr. Gideon Rodan. Bone (2006) 0.75
[The preliminary research in paroxysmal nocturnal hemoglobinuria with thrombosis]. Zhonghua Xue Ye Xue Za Zhi (2016) 0.75
New opportunities for the management of cancer-related bone complications. Clin Adv Hematol Oncol (2009) 0.75